Clinical applications of somatostatin analogs

This publication has 26 references indexed in Scilit:

• Heterogeneity of Growth Hormone (GH) Release by Individual Pituitary Adenoma Cells From Acromegalic Patients, as Determined by the Reverse Hemolytic Plaque Assay: Effects of SMS 201-995, GH-Releasing Hormone and Thyrotropin-Releasing Hormone*
  Journal of Clinical Endocrinology & Metabolism, 1989
• LOCALISATION OF ENDOCRINE-RELATED TUMOURS WITH RADIOIODINATED ANALOGUE OF SOMATOSTATIN
  The Lancet, 1989
• The Role of Somatostatin in the Regulation of Anterior Pituitary Hormone Secretion and the Use of Its Analogs in the Treatment of Human Pituitary Tumors
  Endocrine Reviews, 1988
• Long-acting somatostatin analogue (Sandostatin) reduces late night insulinopenic ketogenesis in diabetic teenagers
  Acta Endocrinologica, 1987
• Treatment of the Malignant Carcinoid Syndrome
  New England Journal of Medicine, 1986
• The Somatostatin Analog SMS 201-995 Induces Long-Acting Inhibition of Growth Hormone Secretion without Rebound Hypersecretion in Acromegalic Patients*
  Journal of Clinical Endocrinology & Metabolism, 1985
• A prospective randomised controlled clinical trial comparing somatostatin and vasopressin in controlling acute variceal haemorrhage.
  BMJ, 1985
• SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged action
  Life Sciences, 1982
• Peptides in the Brain: The New Endocrinology of the Neuron
  Science, 1978
• Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone
  Science, 1973